Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (s)-(1-2-chlorophenyl)-1,2-ethanediol 2-carbamate
2. Rwj 333369
3. Rwj-333369
4. Rwj333369
5. S-2-o-carbamoyl-1-o-chlorophenyl-ethanol
1. Rwj-333369
2. 194085-75-1
3. Ykp-509
4. Jnj-10234094
5. Carisbamate (usan)
6. Carisbamate [usan]
7. (s)-carisbamate
8. P7725i9v3z
9. Rwj-333369-000
10. (s)-2-(2-chlorophenyl)-2-hydroxyethyl Carbamate
11. (2s)-2-(2-chlorophenyl)-2-hydroxyethyl Carbamate
12. (+)-(2s)-2-(2-chlorophenyl)-2-hydroxyethyl Carbamate
13. 1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (1s)-
14. 1,2-ethanediol,1-(2-chlorophenyl)-, 2-carbamate, (1s)-
15. Comfyde
16. Rwj 333369
17. Carisbamate [usan:inn]
18. S-2-o-carbamoyl-1-o-chlorophenyl-ethanol
19. Unii-p7725i9v3z
20. [(2s)-2-(2-chlorophenyl)-2-hydroxyethyl] Carbamate
21. Carisbamate [mi]
22. Carisbamate [inn]
23. Carisbamate [who-dd]
24. Schembl729003
25. Chembl2087003
26. Dtxsid70426076
27. Chebi:135966
28. Zinc30691363
29. Db12338
30. Hy-14948
31. (s)-2-carbamoyloxy-1-o-chlorophenylethanol
32. Cs-0003652
33. D06573
34. (s)-2-o-carbamoyl-1-o-chlorophenyl-ethanol
| Molecular Weight | 215.63 g/mol |
|---|---|
| Molecular Formula | C9H10ClNO3 |
| XLogP3 | 1 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 4 |
| Exact Mass | 215.0349209 g/mol |
| Monoisotopic Mass | 215.0349209 g/mol |
| Topological Polar Surface Area | 72.6 Ų |
| Heavy Atom Count | 14 |
| Formal Charge | 0 |
| Complexity | 201 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Infantile spasms (West Syndrome), Lennox-Gastaut Syndrome, Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, Neonatal seizures, Other paediatric epilepsy syndromes such as Dravet Syndrome, myoclonic astatic syndrome, epilepsy with continuous sharp-waves in sleep, idiopathic partial epilepsy, absence epilepsy
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AX - Other antiepileptics
N03AX19 - Carisbamate
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Carisbamate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carisbamate, including repackagers and relabelers. The FDA regulates Carisbamate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carisbamate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Carisbamate supplier is an individual or a company that provides Carisbamate active pharmaceutical ingredient (API) or Carisbamate finished formulations upon request. The Carisbamate suppliers may include Carisbamate API manufacturers, exporters, distributors and traders.
click here to find a list of Carisbamate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Carisbamate DMF (Drug Master File) is a document detailing the whole manufacturing process of Carisbamate active pharmaceutical ingredient (API) in detail. Different forms of Carisbamate DMFs exist exist since differing nations have different regulations, such as Carisbamate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Carisbamate DMF submitted to regulatory agencies in the US is known as a USDMF. Carisbamate USDMF includes data on Carisbamate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Carisbamate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Carisbamate suppliers with USDMF on PharmaCompass.
Carisbamate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Carisbamate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Carisbamate GMP manufacturer or Carisbamate GMP API supplier for your needs.
A Carisbamate CoA (Certificate of Analysis) is a formal document that attests to Carisbamate's compliance with Carisbamate specifications and serves as a tool for batch-level quality control.
Carisbamate CoA mostly includes findings from lab analyses of a specific batch. For each Carisbamate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Carisbamate may be tested according to a variety of international standards, such as European Pharmacopoeia (Carisbamate EP), Carisbamate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Carisbamate USP).
LOOKING FOR A SUPPLIER?
